OvaScience announces executive management changes
Christophe Couturier has been named Chief Financial Officer.
Mr. Couturier has nearly 20 years of experience with a proven record in management, finance and strategic planning across multiple geographies.
Most recently, he served as Senior Vice President and General Manager at Merck KGaA (Darmstadt, Germany), where he led the Merck KGaA/Pfizer Global Immuno-Oncology Alliance.
Previously, he worked in a series of roles at MilliporeSigma, including serving as Senior Vice President of the Merck KGaA/Sigma-Aldrich Integration Program, Vice President of Corporate Financial Planning and Analysis and Vice President of Finance Operations for the company’s Bioprocess and BioScience divisions.
Prior to joining Merck KGaA in 2004, he worked as an Associate Partner at IBM Business Consulting Services, as a Finance Director at Lloyds Pharmacy and as a Head of Finance for Novartis, with positions in Hungary, Norway, Turkey and Switzerland.
He holds an M.B.A. from ESSEC Business School in France. He succeeds Jeff Young, who is pursuing other opportunities and will be leaving OvaScience after a transition period.
Karen Long joins the Company as Executive Vice President, Clinical and Regulatory Affairs and Quality Assurance.
Ms. Long joins OvaScience from Danaher, Leica Biosystems, where she was Vice President, Regulatory Affairs and Quality Assurance.
Ms. Long has more than 20 years of industry experience, including various senior positions in regulatory affairs at Abbott, Roche Molecular Systems, Inc., Calypte Biomedical Corporation and Baxter Healthcare Therapeutics.
She holds a B.S. in Biochemistry and Medical Technology from the University of Illinois.
James Luterman, OvaScience’s Senior Vice President, Research and Development, has been promoted to Executive Vice President, Research and Development.
Mr. Luterman has been with OvaScience since January 2014 and brings over 20 years of industry experience to the Company. Most recently he served as Senior Vice President, Research and Development at OvaScience.
Prior to OvaScience, Dr. Luterman held various positions at Shire Human Genetic Therapies. He also worked at Biogen and Decision Resources Group.
He holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine. ■
What to read next
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST
Swiss inflation rises in July Economy